1,715
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Future of Helicobacter pylori and its feasibility

&
Pages 733-735 | Received 21 Apr 2018, Accepted 11 Sep 2018, Published online: 17 Sep 2018

The microaerophilic bacterium Helicobacter pylori (H. pylori) is highly adapted to survive in the gastric mucosa of humans where it can persist for several decades [Citation1]. Unfortunately, H. pylori infection is quite common as approximately 50% of the world population is infected with this pathogen. The recognition of H. pylori as the cause of severe gastroduodenal disorders was a massive change not only in the gastroenterology, but also in general medicine [Citation2,Citation3]. After the discovery of the H. pylori by Marshall and Warren, thousands of researchers have conducted investigations to find the exact association of this bacterium with those digestive diseases [Citation4]. Host genetic factors, environmental conditions, and bacterial virulence determinants act together to initiate chronic gastritis, which may result in severe gastroduodenal disorders [Citation3]. Even today the exact mechanisms involved in the pathogenesis of H. pylori are the focus of many laboratories worldwide [Citation3]. The aim of this editorial is to stimulate the discussion on how H. pylori infections can best be treated. Initially, complete eradication of the bacterium was considered as the ideal goal for clinicians and scientists [Citation5,Citation6]. The many published guidelines on the management of this infection are clear evidence of this but in spite of these the worldwide prevalence of the bacterium is still not quickly declining [Citation5,Citation7,Citation8]. In the Western world H. pylori may be slowly disappearing, but this is mostly due to improved housing conditions, lifestyle, and hygiene. These ‘non-treatment’ factors have effectively reduced the infection risks, resulting in the so-called birth cohort effect in the Western world [Citation9]. However, we believe this strong decrease may come to a halt as higher numbers of small children go to creches, daycare, and preschools [Citation10]. Exposure to less hygienic child conditions results in more and more youngsters are infected with difficult to treat (multi) drug resistant H. pylori [Citation11]. While the treatment guidelines in themselves are effective on a per patient basis, we are still far from an ideal form of management of this infection on a national/global scale. The problem with H. pylori eradication treatment is: 1) they are often based on worldwide guidelines (i.e. not including local resistance data) and 2) they are rarely incorporate microbiological susceptibility data of the infecting strains. This because physicians want to quickly cure their patients and culture from biopsies is not only difficult, but also due to the slow growth of H. pylori resistance determination often takes 2 weeks [Citation3]. Hence, solid local microbiological resistance data often lack resulting in empirical choice of antibiotics based on international guidelines.

At the recent, Kyoto global consensus meeting, a unique proposal with respect to the management of H. pylori infections was made and this proposal is the main focus of this editorial [Citation12]. In order to achieve worldwide eradication, the newly proposed guideline defined all H. pylori–colonized persons are candidates to receive an appropriate (empirical) treatment consisting of two antibiotics combined with vonoprazan fumarate (Takecab) as acid blocker.. While one can easily argue that a global eradication of H. pylori by simple antibiotic combination therapy is not a feasible target, Japan has since then launched a program for mass-eradication of this bacterium. The program that primarily targets persons that are at increased risk to develop gastric cancer may diminish the cancer rate, but due to development of antibiotic resistance it may be less effective than estimated. Even when effective, the effect on cancer rates will only be visible in a couple of years. Nevertheless, China and Taiwan also recently started similar programs. To fight the low efficacy rate of antibiotic only therapies, the use of a novel potassium-competitive acid blocker called ‘’Vonoprazan’’ was simultaneously launched in Japan [Citation13]. While studies showed that the use of vonoprazan fumarate increases the efficacy of current anti-H. pylori combination therapy this drug is to our knowledge not commercially available outside Japan.This surely limits the implementation of the antibiotic-based therapy as proposed at the Kyoto consensus. The main advantage of vonoprazan-based triple therapy over traditional PPI-based triple therapy is that activity of the first is less affected by the low gastric pH resulting in higher cure rates [Citation14]. Current evidence suggests that vonoprazan can maintain a high gastric pH, thereby helping to eradicate H. pylori. Due to the acceptable eradication rates in clinical trials performed in recent years, vonoprazan-based triple therapy is highly recommended for H. pylori–colonized patients and persons who are at risk to develop gastric cancer [Citation15,Citation16]. Thus, wide-spread application of vonoprazan in clinical setting for mass-eradication of H. pylori may be an inevitable part of therapeutic regimens in the near future. But one has to realize that vonoprazan is not a wonder drug, and as with other anti-H. pylori triple therapy the effectivity of the combination treatment is predominantly depended on the antibiotic susceptibility of the infecting strain, and a more convenient/effective PPI is not going to change this fact. In spite of the long list of antibiotics, and combinations of antibiotics and supplementary therapeutics, most therapies will become less effective as H. pylori seems able to rapidly develop antibiotic resistance to most of them. This rapid resistance development is largely due to the fact that H. pylori does not require the acquisition of novel genes in order to become resistant as all know resistance is based on mutations in genes already present in its genome [Citation17]. This high resistance has resulted in there not being any reliable nationwide empiric regimen left for a given population [Citation18]. While antibiotic resistance rates are increasing no novel antibiotic are becoming available to fight the resistant bacteria due to the reduced enthusiasm by pharmaceutical companies to invest on new drugs against H. pylori. Therefore, it is to be expected that the Kyoto guideline that once more depends on the eradication of the H. pylori with antibiotics is bound to fail. Given that significant resistance rapidly emerged to all antibiotics used in any previous eradication guideline, it is our opinion that the Kyoto guidelines had better suggested to work on, for example, vaccination as an alternative method of nationwide management of this bacterium [Citation19,Citation20]. The implementation of antibiotics combined with preventive and therapeutic vaccination programs is, in our minds, the only feasible key toward successfully protecting against the severe gastrointestinal disorders associated with H. pylori infection. Unfortunately, vaccination is currently not commercially available, and to our knowledge not many investigators are working on this alternative route. The primary concept of H. pylori vaccination was presented after successful experiments in animal models which reported that protection against other helicobacters could be achieved by antigen-based immunization applied at the mucosal level. Unfortunately, in humans vaccinated individuals did develop an immune response but in spite of this they failed to completely prevent (prophylactic vaccines) or eradicate (therapeutic vaccines) the bacterial colonization. In part this failure could have been predicted as H. pylori is highly variable and unlike most bacteria a change of the serotype does not require a complete exchange of gene clusters but (similar to H. pylori antibiotic resistance) is depending on simple mutations (phase variation) in existing genes [Citation19]. Thus, while neither prophylactic or therapeutic vaccines can prevent or eradicate H. pylori colonization they do reduce the load of the bacterium at the colonized sites [Citation22,Citation23]. This reduced colonization was initially not stressed enough but it may well be enough to delay the development of gastric cancer for a few decades. Unfortunately, most researchers were trying to develop therapeutic vaccines in order to provide a rapid solution for management of H. pylori infections [Citation24,Citation25]. But if one considers the potential effects of achieved bacterial load reduction on long term cancer prevention the limited studies on this subject are promising [Citation26]. In high-risk patients, physicians and patients want more direct effects. For this, one could postulate to first use a vaccine (in order to obtain a bacterial load reduction) followed a few weeks later by a regular antibiotic treatment. This may not only provide enhanced eradication rates, but also as a welcome side effect of the lowered bacterial load also reduce the development of antibiotic resistance. To summarize in our minds simply introducing a new antibiotic-based regime is not going to solve the situation. While vonoprazan is a good enhancement of current antibiotics-based strategies, it is currently only available in Japan and even if it was available worldwide it does not offer a true alternative therapeutic strategy. Unfortunately, safe and reliable vaccines providing protection against H. pylori infection are currently not commercially available at all. Hence, we feel that the key for the future management of this infection should be in promoting research into therapeutic and prophylactic alternatives as only a combination of eradication strategies can provide a solution for the future management of this infection.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

The manuscript was not funded.

References

  • Marcus EA, Scott DR. Gastric colonization by H. pylori. Helicobacter pylori. Singapore: Springer; 2016. p. 23–34.
  • Konturek S, Konturek P, Konturek J, et al. Helicobacter pylori and its involvement in gastritis and peptic ulcer formation. J Physiol Pharmacol. 2006;57:29.
  • Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006;19(3):449–490.
  • Marshall B, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. The Lancet. 1984;323(8390):1311–1315.
  • Malfertheiner P, F M, O’morain C, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report. Gut. 2016:66(1):6-30. gutjnl-2016-312288.
  • Graham DY. Illusions regarding Helicobacter pylori clinical trials and treatment guidelines. Gut 2017. gutjnl-2017-314744.
  • Zagari RM, Romano M, Ojetti V, et al. Guidelines for the management of Helicobacter pylori infection in Italy: the III Working Group Consensus Report 2015. Dig Liver Dis. 2015;47(11):903–912.
  • Malfertheiner P, Megraud F, O’morain CA, et al. Management of Helicobacter pylori infection—the Maastricht IV/Florence consensus report. Gut. 2012;61(5):646–664.
  • Roosendaal R, Kuipers EJ, Buitenwerf J, et al. Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol. 1997;92:1480–1482.
  • Daugule I, Karklina D, Rudzite D, et al. Prevalence of Helicobacter pylori infection among preschool children in Latvia: no significant decrease in prevalence during a ten year period. Scand J Public Health. 2016 Jun;44(4):418–422.
  • Kalach N, Bontems P, Raymond J. Helicobacter pylori infection in children. Helicobacter. 2017;22(Suppl):1)e12414.
  • Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–1367.
  • Garnock-Jones KP. Vonoprazan: first global approval. Drugs. 2015;75(4):439–443.
  • Suzuki S, Gotoda T, Kusano C, et al. The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low-dose clarithromycin triple therapy. Am J Gastroenterol. 2016;111(7):949.
  • Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose‐ranging study of vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Alimentary Pharmacol Therapeutics. 2015;42(6):685–695.
  • Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol. 2015;6(6):e94.
  • Gerrits MM, van Vliet AH, Kuipers EJ, et al. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis. 2006;2:699–709.
  • Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143–1153.
  • Muhsen K, Pasetti MF, Reymann MK, et al. Helicobacter pylori infection affects immune responses following vaccination of typhoid-naive US adults with attenuated Salmonella typhi oral vaccine CVD 908-htrA. J Infect Dis. 2013;209(9):1452–1458.
  • Velin D, Michetti P. Advances in vaccination against Helicobacter pylori. Expert Rev Gastroenterol Hepatol. 2010;4(2):157–166.
  • Nilsson C, Skoglund A, Moran AP, et al. Lipopolysaccharide diversity evolving in Helicobacter pylori communities through genetic modifications in fucosyltransferases. PLoS One. 2008;3(11):e3811.
  • Garhart CA, Redline RW, Nedrud JG, et al. Clearance of Helicobacter pylori infection and resolution of postimmunization gastritis in a kinetic study of prophylactically immunized mice. Infect Immun. 2002;70(7):3529–3538.
  • Sun H, Yuan H, Tan R, et al. Immunodominant antigens that induce Th1 and Th17 responses protect mice against Helicobacter pylori infection. Oncotarget. 2018;9(15):12050.
  • Gong Y, Tao L, Wang F, et al. Chitosan as an adjuvant for a Helicobacter pylori therapeutic vaccine. Mol Med Rep. 2015;12(3):4123–4132.
  • Guo L, Yin R, Xu G, et al. Immunologic properties and therapeutic efficacy of a multivalent epitope‐based vaccine against four Helicobacter pylori adhesins (urease, Lpp20, HpaA, and CagL) in Mongolian gerbils. Helicobacter. 2017;22(6):e12428.
  • Sutton P, Boag JM. Status of vaccine research and development for Helicobacter pylori. Vaccine. 2018. doi.org/10.1016/j.vaccine.2018.01.001

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.